BusinessTetraLogic Pharmaceuticals Corporation Announces Completion of Sale of SMAC Mimetic and HDAC Inhibitor Assets to Medivir ABBy Nasdaq OMXDec 29, 2016, 3:30 PM UTC
BusinessTetraLogic Announces Agreements to Sell SMAC mimetic and HDAC inhibitor assets to Medivir and to Restructure its Convertible Senior Notes and Delisting of Common StockBy Nasdaq OMXNov 2, 2016, 8:30 PM UTC
